MI - 医索

找到约 1407 条结果

Phase lalb trial of zongertinib (Bl 1810631),aHER2-specific tyrosine kinase inhibitor in patients withHER2 aberration-positive solid tumors updatedPhase la data from Beamion LUNG-1, includingprogression-

医客学院 - 会议报告集

NRG-LU002Randomized Phase lllll Trial Of MaintenanceSystemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer

医客学院 - 会议报告集

Milestones Early Detection to Nodal Status and Every thing in Between

医客学院 - 会议报告集

Ivonescimab combined with chemotherapy in patientswith EGFR-mutant non-squamous non-small cell lungcancer who progressed on EGFR-TKls treatment arandomized, double-blind, multi-center, phase 3 trial(HARM

医客学院 - 会议报告集

Health-Related Quality of Life Outcomes From the Randomized, Double-Blind Phase 3 KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC

医客学院 - 会议报告集

BEAT-SC A randomized phase lll study ofbevacizumab or placebo in combination withatezolizumab and platinum-based chemotherapy inpatients with extensive-stage small cell lung cancer

医客学院 - 会议报告集

Amivantamab plus lazertinib vs osimertinib infirst-line EGFR-mutant advanced non-small cell lungcancer(NSCLC)with biomarkers of high-risk diseaseA secondary analysis from the phase 3 MARIPOSA study

医客学院 - 会议报告集

Amivantamab plus lazertinib in atypical EGFR-mutatedadvanced non-small cell lung cancer (NSCLC)Results from CHRYSALIS-2

医客学院 - 会议报告集

Amivantamab and lazertinib inpatients with EGFR-mutant lungcancers and CNS disease

医客学院 - 会议报告集

Adjuvant icotinib of 12 months or 6 months versus observationfollowing adjuvant chemotherapy for resected EGFR-mutatedstage ll-lllA non-small-cell lung cancer (ICTAN, GASTO1002) arandomized phase 3 trial

医客学院 - 会议报告集

今日实时热搜